Drug Profile
BMS 830216
Alternative Names: BMS-830216Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Obesity therapies
- Mechanism of Action MCHR1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 07 Nov 2013 Discontinued - Phase-I/II for Obesity in USA (PO)
- 30 Jun 2011 Bristol-Myers Squibb completes a phase I/II trial for Obesity in USA (NCT00909766)
- 16 Jun 2011 Bristol-Myers Squibb completes enrolment in its phase I/II trial for Obesity in USA (NCT00909766)